Bliss Gvs Pharma Limited (BLISSGVS) AI Stock Analysis

• Market Cap: ₹16.49B
• Dividend Yield: 0.32%
• Average Volume (3M): 43.54K
• Price to Earnings (P/E): 15.3
• Beta (1Y): 1.44
• Revenue Growth: 4.93%
• EPS Growth: 29.92%
• Country: IN
• Employees: 831
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.08
• Shares Outstanding: 105,649,475
• 10 Day Avg. Volume: 54,046
• 30 Day Avg. Volume: 43,538
• PEG Ratio: 1.37
• Price to Book (P/B): 1.20
• Price to Sales (P/S): 1.56
• P/FCF Ratio: 42.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 69 Neutral
• Price Target: ₹171.00 ▲(9.72% Upside)

Bliss Gvs Pharma Limited's strong financial performance, characterized by consistent revenue growth and a solid balance sheet, is the primary driver of its stock score. The technical analysis indicates some short-term weakness, while the valuation suggests the stock is fairly priced. The absence of earnings call data and corporate events means these factors do not influence the score.

Bliss Gvs Pharma Limited Business Overview & Revenue Model

Company Description

Bliss Gvs Pharma Limited (BLISSGVS) is a leading pharmaceutical company based in India, specializing in the development and manufacturing of a wide range of pharmaceutical products, including formulations, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) medications. The company primarily operates in the sectors of generic pharmaceuticals and specialty formulations, catering to both domestic and international markets. With a focus on quality and innovation, Bliss Gvs Pharma is dedicated to providing affordable healthcare solutions across various therapeutic areas.

How the Company Makes Money

Bliss Gvs Pharma generates revenue through multiple streams, primarily from the sale of its pharmaceutical formulations and APIs. The company has established a solid presence in both domestic and international markets, leveraging partnerships with distributors and healthcare providers to expand its reach. Key revenue streams include sales of generic drugs, specialty medications, and OTC products. Additionally, Bliss Gvs Pharma benefits from strategic alliances and collaborations with other pharmaceutical companies, which enhance its product offerings and market penetration. By investing in research and development, the company aims to introduce new products, thereby driving future growth and profitability.

Bliss Gvs Pharma Limited Financial Statement Overview

Summary

Bliss Gvs Pharma Limited exhibits a robust financial performance with consistent revenue growth and improved profit margins. The strong balance sheet with low leverage and high equity ratio is a key strength. However, cash flow management could be optimized to enhance liquidity.

Income Statement

Bliss Gvs Pharma Limited has shown consistent revenue growth over the years, with a notable increase in gross and net profit margins in the latest year. The EBIT and EBITDA margins have improved, indicating efficient cost management and operational performance. While the revenue growth trajectory is positive, there could be improved consistency in EBITDA performance.

Balance Sheet

The company maintains a strong balance sheet with a high equity ratio and low debt-to-equity ratio, showcasing financial stability and low leverage. The return on equity has seen improvement, reflecting the company's ability to generate profits from shareholders' equity. The company's strong equity position is a key strength.

Cash Flow

The cash flow position has been mixed, with variability in free cash flow growth rates. The operating cash flow to net income ratio indicates a healthy cash conversion cycle, but the free cash flow to net income ratio suggests room for improvement. The company should focus on optimizing capital expenditures to enhance free cash flow.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.34B	8.10B	7.66B	7.47B	7.38B	5.69B
Gross Profit	3.79B	3.96B	2.49B	3.50B	3.47B	2.40B
EBITDA	2.02B	1.27B	1.49B	1.35B	762.37M	1.27B
Net Income	1.07B	842.99M	754.54M	708.59M	150.40M	684.91M
Balance Sheet
Total Assets	0.00	13.01B	12.14B	11.57B	11.09B	10.77B
Cash, Cash Equivalents and Short-Term Investments	1.41B	1.41B	1.41B	684.11M	1.35B	616.64M
Total Debt	0.00	881.04M	998.40M	1.02B	1.09B	1.22B
Total Liabilities	-10.92B	2.09B	2.11B	2.39B	2.62B	2.49B
Stockholders Equity	10.92B	10.50B	9.67B	8.84B	8.19B	8.08B
Cash Flow
Free Cash Flow	0.00	298.48M	1.24B	-594.86M	614.77M	548.45M
Operating Cash Flow	0.00	1.06B	1.52B	343.13M	1.35B	639.69M
Investing Cash Flow	0.00	-754.41M	-1.33B	-77.51M	-929.75M	-469.91M
Financing Cash Flow	0.00	-303.45M	-208.93M	-249.38M	-237.30M	-207.98M

Bliss Gvs Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 155.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLISSGVS, the sentiment is Positive. The current price of 155.85 is above the 20-day moving average (MA) of 152.77, below the 50-day MA of 156.75, and above the 200-day MA of 144.44, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 52.02 is Neutral, neither overbought nor oversold. The STOCH value of 41.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BLISSGVS.

Bliss Gvs Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JAGSNPHARM	69 Neutral	₹14.80B	23.91	―	1.13%	34.72%	196.94%
BLISSGVS	69 Neutral	₹16.49B	15.33	―	0.32%	4.93%	29.92%
WINDLAS	69 Neutral	₹19.62B	29.81	―	0.62%	20.19%	8.71%
SYNCOMF	65 Neutral	₹15.38B	26.72	―	―	70.43%	101.61%
HESTERBIO	61 Neutral	₹14.73B	38.76	―	0.41%	4.68%	94.22%
BAJAJHCARE	54 Neutral	₹14.41B	30.97	―	0.22%	13.04%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%